Skip to main content

and
  1. No Access

    Article

    Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

    Mutations in genes of the RAS family are preset on about 20% of human cancers, making RAS proteins prime potential targets for cancer therapy. Direct targeting of RAS proteins has not so far been productive, but ...

    David A. Barbie, Pablo Tamayo, Jesse S. Boehm, So Young Kim, Susan E. Moody in Nature (2009)